Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

David M. Ross, Ilaria S. Pagani, Yazad D. Irani, Jade Clarson, Tamara Leclercq, Phuong Dang, Jennifer McLean, Verity A. Saunders, Lisa Carne, John Reynolds, David S. Ritchie, Deborah L. White, Susan Branford, Timothy P. Hughes, Agnes S.M. Yong

Research output: Contribution to journalLetterOtherpeer-review

4 Citations (Scopus)
Original languageEnglish
Pages (from-to)e56-e60
Number of pages5
JournalBritish Journal of Haematology
Volume186
Issue number3
DOIs
Publication statusPublished - Aug 2019

Keywords

  • chronic myeloid leukaemia
  • immunology
  • treatment-free remission
  • minimal residual disease

Cite this

Ross, D. M., Pagani, I. S., Irani, Y. D., Clarson, J., Leclercq, T., Dang, P., McLean, J., Saunders, V. A., Carne, L., Reynolds, J., Ritchie, D. S., White, D. L., Branford, S., Hughes, T. P., & Yong, A. S. M. (2019). Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British Journal of Haematology, 186(3), e56-e60. https://doi.org/10.1111/bjh.15894